Norris Cotton Cancer Center, Hanover, NH
Muhammad Zubair Afzal , Flanklin E. Corea-Dilbert , Bret Wankel , John P. Palmer , Jonathan P. Pirruccello , Soham Kale , Aditya Sharma , Ziyao Lu , Samer Ibrahim , Yuanzhen Cao , Tayyaba Sarwar , Keisuke Shirai
Background: Circulating tumor DNA (ctDNA) is tumor-derived fragment of DNA circulating in plasma. ctDNA has been used to detect minimal residual disease (MRD) in early-stage cancers after curative intent therapy. However, ctDNA based MRD concept is not investigated in metastatic disease. There is a lack of clarity around optimal timing to stop immune checkpoint inhibitors (ICI) in melanoma and lung cancer patients who have achieved durable response (DR) and MRD may have a role here to select right patients to stop therapy at an optimal time. Methods: This is prospective study on metastatic lung cancer and melanoma patients with DR treated with ICI. DR is identified as objective response (CR/PR) by modified WHO criteria lasting ≥6 months continuously. We utilized Signatera assay by Natera. Signatera uses tissue from original biopsy of the patients and develop multiplex PCR based personalized assay to detect MRD. The level of ctDNA is reported in mean tumor molecules per mL. We obtained ctDNA assay at baseline, month 3 and month 6 at their routine follow up visits. If applicable, ctDNA assay was done at the time of progression, and 3 months after resuming treatment. Results: We identified 29 melanoma and 17 Lung cancer (both small cell and non-small cell) patients with metastases and DR. Median age was 69 years in both cohorts. Median duration of ICI was 14 months in melanoma and 24 months in lung cancer cohort. ctDNA assay was obtained in 26 melanoma and 13 lung cancer patients. One small cell lung cancer patient had detectable ctDNA at baseline, although radiographically, the patient had DR. The rest of the patients in both cohorts had undetectable ctDNA. 2 melanoma patients developed detectable ctDNA on subsequent assays and their therapies were changed. One small cell lung cancer patient has persistently detectable ctDNA on subsequent assays but remained in DR. A total of 10 patients in both cohorts decided to stop their therapy following several -ve ctDNA assay. Conclusions: The role of ctDNA needs to be investigated in advanced/metastatic settings as MRD may have a role to identify patients who may benefit from treatment break. MRD surveillance may also support radiographic assessment.
Melanoma (N = 29) | Lung Cancer (N = 17) | |
---|---|---|
Age (median) Years | 69 (35 – 89) | 69 (49 – 79) |
Gender Male Female | 18 11 | 10 7 |
Median Duration of ICI (Months) Median Number of ICI Cycles | 14 (2 – 78) months 16 (3 – 81) | 24 (9 – 78) months 23 (7 – 78) |
Median Time to BR | 5.3 (1.5 – 18) months | 8 (1.5 – 36.5) months |
Durable Response | 26 (13 CR, 13 PR) | 17 (11 CR, 6 PR) |
ctDNA Patients with Serial ctDNA | 26 Patients (3 NET) 17 | 13 Patients (4 NET) 7 |
Detectable ctDNA on 1st Surveillance Detectable ctDNA on Subsequent Surveillance | 0/26 2/17 | 1/13 (4 NET) 1/7 |
Ongoing Therapy at ctDNA | 14 | 10 |
Patients Stopping Therapy at Negative ctDNA | 6/26 | 4/13 |
Detectable ctDNA after Stopping Therapy | 0 | 0 |
Continuous Response after -ve ctDNA | 5 | 0 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Quality Care Symposium
First Author: Alia Rawji
2023 ASCO Annual Meeting
First Author: Christoffer Gebhardt
2023 ASCO Annual Meeting
First Author: Julian Taugner
2023 ASCO Annual Meeting
First Author: Fatemeh Ardeshir-Larijani